InvestorsHub Logo
Followers 15
Posts 1222
Boards Moderated 0
Alias Born 12/16/2020

Re: None

Tuesday, 05/04/2021 3:20:16 PM

Tuesday, May 04, 2021 3:20:16 PM

Post# of 426330
It is stunning to think that we are about $1.80 away from the stock price just prior to the REDUCE-IT results. Since then we have:

- Increased our cash balance to over $500 Mil
- Have FDA approval as the only drug approved for CV risk reduction
- Approval in Canada for same
- Approval in EU for same
- Approval in UK for same
- Pending approval in China for same
- Evidence of plaque reduction in arteries (EVAPORATE)
- Anecdotal evidence of mitigation of severe Covid symptoms
- Incoming CEO with Sales and Drug launch experience
- Change in General Council
- Pending infringement litigation against Hikma and Health
- Pending Supreme Court uptake

We got DUped out of the Marine patent but we still control the API market and can launch our own gV if needed.

Covid is on a sharp decline in the US and will continue to be so. I still think we are slow walking the US market until Hikma bleeds money on their ill fated gV launch.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News